10/582621

	•	1.	173 HEC 0.70	A DEPARTMENT OF COMMERCE			
· s	bstitute for form 1449A/PTO			COMPLETE IF KNOWN			
I	NFORMATION	DIS	CLOSURE	Application Number			
	TATEMENT BY	A T	DI ICANE	Filing Date	A		
3	IAIEMENI BY	Ar	PLICANI	First Named Inventor	Pallaoro, et al.		
				Group Art Unit	1633		
	(use as many sheets	as r	ecessary)	Examiner Name	Marvich		
Sheet	1	of	4	Attorney Docket Number	ITR0053YP		

		U.S. Patent Document	0.0	TENT DOCUMENTS	
xaminer nitials*	Cite No.	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
/M.M		5,741,657		Tsien, et al.	04/21/1998
		5,807,692		Kinzler, et al.	09/15/1998
		5,871,968		Kinzler, et al.	02/16/1999
		5,955,604		Tsicn, ct al.	09/21/1999
		5,993,845		Geerts, et al.	11/30/1999
		6,068,987		Dulski, et al.	05/30/2000
		6,291,162 B1	-	Tsien, et al.	09/18/2001
		6,387,673 B1		Evans, et al.	05/14/2002
$\neg \sqcap$		6,472,205 B1		Tsien, et al.	10/29/2002
$\neg \sqcap$		6,511,990 B1		Breslow, et al.	01/28/2003
		6,541,661 B1		Delorme, et al.	04/01/2003
V		6,544,957 B1		Kern, et al.	04/08/2003
/M.M	/	6,638,530 B1		Ishibashi, et al.	10/28/2003

		_	Foreign Patent Documer		DOCUMENTS	
Examiner nitials*	Cite No.	Office		Kind Code ((f known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
/M.M.		PCT	WO 96/30540		The Regents of the Univ. of Califo	rnia 10/03/1996
/M.M	/	PCT	WO 99/50280		Trustees of the Univ. of Pennsylva	
/M.M.	,	PCT	WO 03/020930		The Board of Trustees of the Univ	of 03/13/2003
			,			
Examin Signatur		/8.4	aria Marvich/		Date Considered	10/25/2008

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with neut communication to applicate. SEND TO: Commissioner for Platents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated from * (Dis Fowler), Merck & Co., Inc., -7/12/2005.

10/582621
SUBSTITUTE for TIONBOOK 407-05). Information Dischourer Statements by Applicate
Substitute for TIONBOOK 407-05). Information Dischourer Statements by Applicate
Substitute for TIONBOOK 407-05). Information Dischourer Statements by Applicate
Substitute for TIONBOOK 407-05). Information Dischourer Statements by Applicate
Substitute for TIONBOOK 407-05). Information Dischourer Statements by Applicate
Substitute for TIONBOOK 407-05). Information Dischourer Statements by Applicate
Substitute for TIONBOOK 407-05). Information Dischourer Statements by Applicate
Substitute for TIONBOOK 407-05). Information Dischourer Statements by Applicate
Substitute for TIONBOOK 407-05). Information Dischourer Statements by Applicate
Substitute for TIONBOOK 407-05). Information Dischourer Statements by Applicate
Substitute for TIONBOOK 407-05). Information Dischourer Statements by Applicate
Substitute for TIONBOOK 407-05). Information Dischourer Statements by Applicate
Substitute for TIONBOOK 407-05). Information Dischourer Statements by Applicate
Substitute for TIONBOOK 407-05). Information Dischourer Statements by Applicate
Substitute for TIONBOOK 407-05). Information Dischourer Statements by Applicate
Substitute for TIONBOOK 407-05). Information Dischourer Statements by Applicate
Substitute for TIONBOOK 407-05). Information Dischourer Statements by Applicate for TIONBOOK 407-05). Information Dischourer Statements by Applicate for TIONBOOK 407-05. Information Dischourer Statements by Appli

COMPLETE IF KNOW	NN
Substitute for form 1449B/PTO	···
INFORMATION DISCLOSURE Application Number	
STATEMENT BY APPLICANT	
First Named Inventor Pallaoro, et al.	
Group Art Unit	
(use as many sheets as necessary) Examiner Name	
eet 2 of 4 Attorney Docket Number ITR0053YP	

_				
	_		NON PATENT LITERATURE DOCUMENTS	
Examiner Cite Include name of the author, title, date, page(s), volume-issue number(s) and place of publication Include name of the author, title, date, page(s), volume-issue number(s) and place of publication Include name of the author, title, date, page(s), volume-issue number(s) and place of publication Include name of the author, title, date, page(s), volume-issue number(s) and place of publication Include name of the author, title, date, page(s), volume-issue number(s) and place of publication Include name of the author, title, date, page(s), volume-issue number(s) and place of publication Include name of the author, title, date, page(s), volume-issue number(s) Include name of the author, title, date, page(s), volume-issue number(s) Include name of the author, title, date, page(s), volume-issue number(s) Include name of the author, title, date, page(s), volume-issue number(s) Include name of the author, title, date, page(s), volume-issue number(s) Include name of the author, title, date, page(s), volume-issue number(s) Include name of the author, title, date, page(s), volume-issue number(s) Include name of the author, title, date, page(s), volume-issue number(s) Include name of the author, title, date, page(s), volume-issue number(s) Include name of the author, title, date, page(s), volume-issue number(s) Include name of the author, title, date, page(s), volume-issue number(s) Include name of the author, title, date, page(s), volume-issue number(s) Include name of the author, title, date, page(s), volume-issue number(s) Include name of the author, title, date, page(s), volume-issue number(s) Include name of the author, title, date, page(s), volume-issue number(s) Include name of the author, title, date, page(s), volume-issue number(s) Include name of the author, title, date, page(s), volume-issue number(s) Include name of the author, title, date, page(s), volume-issue number(s) Include name of the author, title, date, page(s), volume-issue number(s) Inc				
/M	/M.M./		Archer, et al., "Histone acetylation and cancer", Curr. Opin. Genet. Devel., Vol. 9, pp. 171-174, 1999.	
			Archer, et al., "p21WAF1 is required for butyrate-mediated growth inhibition of human colon cancer cells", PNAS USE, Vol. 95, pp. 6791-6796, June 1998.	
			Colletti, et al., "Tryptophan-replacement and indole-modified apicidins: synthesis of potent and selective antiprotozoal agents", Tetrahedron Letters, Vol. 41, pp. 7825-7829, 2000.	
T			Colletti, et al., "Design and synthesis of histone deacetylase inhibitors: the development of apicidin transition state analogs", Tetrahedron Letters, Vol. 41, pp. 7837-7847, 2000.	
T			Colletti, et al., "Broad Spectrum Antiprotozoal Agents that Inhibit Histone Deacetylase: Structure-Activity Relationships of Apicidin. Part 1", Bioorganic & Medicinal Chemistry Letters, Vol. 11, pp. 107-111, 2001.	
			Colletti, et al., "Broad Spectrum Antiprotozoal Agents that Inhibit Histone Deacetylase: Structure-Activity Relationships of Apicidin. Part 2", Bioorganic & Medicinal Chemistry Letters, Vol. 11, pp. 113-117, 2001.	
			Cress, et al., "Histone Deacetylases, Transcriptional Control, and Cancer", J. of Cellular Physiol., Vol. 184, pp. 1-16, 2000.	
			Egawa, et al., "Identification of Active Substances from Streptomyces Culture Fluids Using p53-Independent Expression of p21/WAF1/Cip1 Gene and Their Mode of Action", Biol. Pharm. Bull. Vol. 21, Issue 9, pp. 899-904, 1998	
			Furumai, et al., "FK228 (Depsipeptide) as a Natural Prodrug That Inhibits Class I Histone Deacetylases", Cancer Research, Vol. 62, pp. 4916-4921, 2002.	
			Galarneau, et al., "β-lactamase protein fragment complementation assays as in vivo and in vitro sensors of protein-protein interactions", Nature Biotechnology, pp. 319-622, 2002.	
			GenBank Accession No. AF497972	
	GenBank Ac		GenBank Accession No. U24170	
			GenBank Accession No. 285996	
	,		Grozinger, et al., "Deacetylase Enzymes: Biological Functions and the Use of Small-Molecule Inhibitors", Chemistry & Biology, Vol. 9, pp. 3-16, 2002.	
/M	.м./		Han, et al., "Activation of p21WAF1/Cip1 Transcription through Sp1 Sites by Histone Deacetylase Inhibitor Apicidin", J. Biol. Chem., Vol. 276, pp. 42084-42090, 2001.	

Examiner Signature	/Maria Marvich/	,	Date Considered	10/25/2008

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form * IDS Form* (IDS Folder), Merck & Co., loc., -7/12/2005 10/582621 1403 Rep. d PCT/PTO 1 2 whith a complete of the control of the control

		į	AP3 Rec'o Pu	INTIO I ZOUTE	PTO/BB/08A (07-05), Information Disclosure Statement by Applicant White and Trademark Office; U.S DEPARTMENT OF COMMERCE
· s	ubstitute for form 1449B/PTO				OMPLETE IF KNOWN
I	NFORMATION	DIS	CLOSURE	Application Number	
6	TATEMENT BY		DLICANT	Filing Date	_
3	IAIEMENIDI	Ar	PLICANI	First Named Inventor	Pallaoro, et al.
				Group Art Unit	
	(use as many sheets	as r	necessary)	Examiner Name	
Sheet	3	of	4	Attorney Docket Number	ITR0053YP

		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
Huang, et al., "Activation of the p21WAF1/CIP1 promoter independent of		Huang, et al., "Activation of the p21WAFI/CIP1 promoter independent of p53 by the histone deacetylase indires suberoylamlide hydroxyamic acid (SAHA) through the Sp1 sites", Oncogene, Vol 19, pp. 5712-5712, 2000.
		Johnstone, et al., "Histone-Deacetylase Inhibitors: Novel Drugs For The Treatment of Cancer", Nature Reviews/ Drug Discovery, Vol. 1, pp. 287-299, 2002.
		Ju, et al., "Histone Deacetylase Inhibitors Activate p21WAF1 Expression via ATM", Cancer Research, Vol. 63, pp. 2891-2897, 2003.
		Kramer, et al., "Histone deacetylase as a therapeutic target", Trends Endocrin. Metabol., Vol. 12, pp. 294-300, 2001.
		Marks, et al., "Histone Deacetylases and Cancer: Causes and Therapies", Nature Reviews/Cancer, Vol. 1, pp. 194-202, 2001.
		Meinke, et al., "Histone Deacetylase: A Target for Antiproliferative and Antiprotozoal Agents", Current Medicinal Chemistry, Vol. 8, pp. 211-235, 2001.
		Meinke, et al., "Synthesis of Apicidin-Derived Quinolone Derivatives: Parasite-Selective Histone Deacetylase Inhibitors and Antiproliferative Agents", J. Med. Chem., Vol. 43, pp. 4919-4922, 2000.
		Meinke, et al., "Synthesis of side chain modified apicidin derivatives: potent mechanism-based histone deacetylase inhibitors", Tetrahedron Letters, Vol. 41, pp. 7831-7835, 2000.
		Nakano, et al., "Butyrate Activates the WAF1/Cip1 Gene Promoter through Sp1 Sites in a p53-negative Human Colon Cancer Cell Line*", J. of Biol. Chem., Vol. 272, No. 35, pp. 22199-22206, 1997.
		Nare, et al., "Development of a Scintillation Proximity Assay for Histone Deacetylase Using a Biotinylated Peptide Derived from Histone-H4", Analytical Biochemistry, Vol. 267, pp. 390-396, 1999.
		Perez, et al., "Discovery and SAR of NVP-LAQ824, a novel histone deacetylase inhibitor with in vitro and in vivo antitumor activity", Proc. Am. Assoc. Cancer Res., Vol. 43, Vol. 740, #3671, 2002.
		Richon, et al., "Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation", PNAS, Vol. 97, No. 18, pp. 10014-10019, 2000.
		Sambucetti, et al., "Histone Deacetylase Inhibition Selectively Alters the Activity and Expression of Cell Cycle Proteins Leading to Specific Chromatin Acetylation and Antiproliferative Effects", J. of Biol. Chem., Vol. 274, No. 49, pp. 34940-34947, 1999.
\bigvee		Sowa, et al., "Histone Deacetylase Inhibitor Activates the WAF1/Clp1 Gene Promoter through the SP1 Sites", Biochem. and Biophys. Res. Comm., Vol. 241, pp. 142-150, 1997.
/M.M.		Sowa, et al., "Sp3, but not Sp1 Mediates the Transcriptional Activation of the P21/WAF1,Cip1 Gene Promoter by Histone Deacetylase Inhibitor", Cancer Research, Vol. 59, pp. 4266-4270, 1999.

Examiner /Maria Marvich/ Date 10/25/2008				
Signature Considered	Examiner Signature	/Maria Marvich/	Considered	10/25/2008

10/582621

_			P3 Hec O PCIT		PRIME and Trademark Office; U.S DEPARTMENT OF COMMERCE
-	ubstitute for form 1449B/PTO NFORMATION 1	DIS	CLOSURE	Application Number	
	TA TENATENIT DAY	4 T	DI ICANET	Filing Date	
STATEMENT BY APPLICANT				First Named Inventor	Pallaoro, et al.
			,	Group Art Unit	
(use as many sheets as necessary)			ecessary)	Examiner Name	
eet	4	of	4	Attorney Docket Number	ITR0053YP

Sheet		4 of Austral December 118003311						
	_	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.						
/M.M./		aunton, et al., "A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p", cience, Vol. 272, pp. 408-411, 1996.						
/M.M./		/igushin, et al., "Histone deacetylase inhibitors in cancer treatment", Anti-Cancer Drugs, Vol. 13, pp. 1-13, 002.						
/M.M	/	Giao, et al, "Both Sp1 and Sp3 Are Responsible for p21waf1 Promoter Activity Induced by Histone beacetylase Inhibitor in NIH3T3 Cells", J. of Cell. Biol., Vol. 73, pp. 291-302, 1999.						
/M.M.		ing, et al., "A Fluorescent Reporter Assay for the Detection of Ligands Acting Through G1 Protein-Coupled eceptors", J. Recept. Signal Transduct. Res., Vol. 20, pp. 189-210, 2000.						
/M.M./		Zlokarnik, et al., "Quantitation of Transcription and Clonal Selection of Single Living Cells with β- actamase as Reporter", Science, Vol. 279, pp. 84-88, 1988.						
-								

			40/05/0000
Examiner Signature	/Maria Marvich/	Date Considered	10/23/2000

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applican.